Skip to Main Content

Author Details

Henrik Gr??nberg
Karolinska Institute
1993
368
79
PMIDPaper TitleJournal TitlePublished Year
36762756Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer.Clin Chem2023
37945903Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.Nat Genet2023
37606002[Improved prostate cancer diagnostics with a structured pathway including »Stockholm 3« test, MRI and targeted perineal biopsies].Lakartidningen2023
36522257External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.Eur Urol Focus2023
37091033Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer.Eur Urol Open Sci2023
36762756Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer.Clin Chem2023
37311464Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.Am J Hum Genet2023
37292833Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry.medRxiv2023
37292496<i>AR</i> and <i>PI3K</i> Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer.Eur Urol Open Sci2023
37945903Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.Nat Genet2023
37606002[Improved prostate cancer diagnostics with a structured pathway including »Stockholm 3« test, MRI and targeted perineal biopsies].Lakartidningen2023
37292833Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry.medRxiv2023
37292496<i>AR</i> and <i>PI3K</i> Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer.Eur Urol Open Sci2023
37311464Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.Am J Hum Genet2023
37091033Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer.Eur Urol Open Sci2023
36522257External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.Eur Urol Focus2023
35094896Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.Eur Urol2022
35595235Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks.Bioinformatics2022
35587340Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.JAMA Oncol2022
35813248External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.Eur Urol Open Sci2022
35495282A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.Eur Urol Open Sci2022
35367086Corrigendum to "Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study" [Eur Urol 2022].Eur Urol2022
36185581Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening.Eur Urol Open Sci2022
35317973Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer.Eur Urol Focus2022
35152271Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.Prostate Cancer Prostatic Dis2022
35094896Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.Eur Urol2022
35587340Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.JAMA Oncol2022
35495282A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.Eur Urol Open Sci2022
35367086Corrigendum to "Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study" [Eur Urol 2022].Eur Urol2022
35595235Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks.Bioinformatics2022
35813248External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.Eur Urol Open Sci2022
36185581Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening.Eur Urol Open Sci2022
35317973Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer.Eur Urol Focus2022
35152271Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.Prostate Cancer Prostatic Dis2022
32641739Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort.Prostate Cancer Prostatic Dis2021
33591326Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML.Blood Adv2021
34237810MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.N Engl J Med2021
33808193Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer.Cancers (Basel)2021
33473200Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.Nat Genet2021
33623038Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.Nat Commun2021
34337495The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects.Eur Urol Open Sci2021
34337490Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms.Eur Urol Open Sci2021
32641739Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort.Prostate Cancer Prostatic Dis2021
32866231Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).J Natl Cancer Inst2021
32734463Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer.World J Urol2021
33168965Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test.Prostate Cancer Prostatic Dis2021
33420416Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.Prostate Cancer Prostatic Dis2021
33398198Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.Nat Genet2021
33436325Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.Eur Urol Oncol2021
34678156A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.Lancet Oncol2021
  • 1 - 50 of 736

Recommended Authors

Travis Gerke
The Prostate Cancer Clinical Trials Consortium
Career Start Year 2014
Number of shared co-authors 26
Kristina M Jordahl
University of Washington
Career Start Year 2014
Number of shared co-authors 22
Irene Casanova-Salas
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2012
Number of shared co-authors 3
Mieke Van Hemelrijck
School of Cancer and Pharmaceutical Sciences, King's College London
Career Start Year 2007
Number of shared co-authors 14
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 16
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 26
Mine S Cicek
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 81
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 10
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 21
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 32
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 33
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 21
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 12
Maciej Kwiatkowski
University of Basel, Academic Hospital Braunschweig
Career Start Year 1998
Number of shared co-authors 10
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 28
Franklin W Huang
Institute for Human Genetics, University of California san francisco
Career Start Year 1998
Number of shared co-authors 14
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 16
Niall M Corcoran
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 33
Stephen J Freedland
Cedars-Sinai Medical Center
Career Start Year 1996
Number of shared co-authors 35
Penny Flohr
The Institute of Cancer Research
Career Start Year 1993
Number of shared co-authors 29
Peter S Nelson
Fred Hutchinson Cancer Center
Career Start Year 1993
Number of shared co-authors 40
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 21
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 19
Timothy R Rebbeck
Center for Cancer Equity and Engagement, Dana-Farber/Harvard Cancer Center
Career Start Year 1991
Number of shared co-authors 152
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 20
N??ria Malats
Spanish National Cancer Research Centre
Career Start Year 1989
Number of shared co-authors 86
Adrie van Bokhoven
University of Colorado Anschutz Medical Campus
Career Start Year 1988
Number of shared co-authors 8
Heather Thorne
Peter MacCallum Cancer Centre
Career Start Year 1982
Number of shared co-authors 60
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 52
Gloria M Petersen
Mayo Clinic
Career Start Year 1979
Number of shared co-authors 104

Collaborators

Fredrik Wiklund
Co-authored papers 155
Jianfeng Xu
Co-authored papers 101
William B Isaacs
The Brady Urological Institute, The Johns Hopkins School of Medicine
Co-authored papers 82
Zsofia Kote-Jarai
The Institute of Cancer Research
Co-authored papers 58
Rosalind A Eeles
The Institute of Cancer Research
Co-authored papers 58
Douglas F Easton
University of Cambridge
Co-authored papers 57
Johanna Schleutker
Institute of Biomedicine, University of Turku
Co-authored papers 55
Janet L Stanford
Fred Hutchinson Cancer Research Center
Co-authored papers 53
Christopher A Haiman
University of Southern California
Co-authored papers 49
David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 48
Stephen N Thibodeau
Mayo Clinic
Co-authored papers 48
Graham G Giles
Co-authored papers 45
Ruth C Travis
Co-authored papers 45
Cezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 44
Johan Lindberg
Karolinska Institute
Co-authored papers 43
Sonja I Berndt
Co-authored papers 43
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 42
John D Carpten
Co-authored papers 40
Kay-Tee Khaw
Co-authored papers 40
Børge G Nordestgaard
Co-authored papers 39
David J Hunter
The Kolling Institute, University of Sydney, and Royal North Shore Hospital
Co-authored papers 37
Freddie C Hamdy
University of Oxford
Co-authored papers 36
Peter Kraft
Harvard T. H. Chan School of Public Health
Co-authored papers 34
Lars Egevad
Karolinska Institute
Co-authored papers 32
Daniel J Schaid
Mayo Clinic
Co-authored papers 32
Fredrick R Schumacher
Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine
Co-authored papers 32
Demetrius Albanes
Co-authored papers 29
Loic Le Marchand
Co-authored papers 29
Shannon K McDonnell
Mayo Clinic
Co-authored papers 27
Judith A Clements
Co-authored papers 25
Release 1.2